FDA approves new drug that slows cognitive decline from Alzheimer's

The Food and Drug Administration recently approved a new medication from Eli Lilly that works to clear protein clumps associated with Alzheimer’s disease from the brain. The medication, sold under the brand name Kisunla, is only the second drug on the market aimed at slowing the progression of the debilitating neurological disease.

Here & Now‘s Scott Tong speaks with STAT reporter Elaine Chen about what this moment means for the Alzheimer’s community.

This article was originally published on WBUR.org.